Evidence map›Paper›PMID 32612947›Full record

ReviewFrontiers in oncology2020

Breast Cancer Survivorship, Quality of Life, and Late Toxicities.

Simone Nardin, Edoardo Mora, Feba Mariam Varughese, Francesca D'Avanzo, Ajay Ram Vachanaram, Valentina Rossi, Chiara Saggia, Sara Rubinelli, Alessandra Gennari

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 188 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07140107 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Patients' Perceptions and Comprehension of Original Versus AI-Generated Plain Language Summaries of Cochrane Oncology Systematic Reviews

TypeinterventionalSponsorUniversity of Split, School of MedicineRan2025 to 2026Enrolled130ConditionsNon-Metastatic Breast CancerArmsAI-generated PLS, Original PLS
NCT07253987 narecruitingnot on this mapstarted 2025, after this paper: background citation

Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer

TypeinterventionalSponsorMasaryk Memorial Cancer InstituteRan2025 to 2026Enrolled200ConditionsProstate Cancer Patients, Breast Cancer PatientsArmsactive screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening
3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Psychosocial experiences of breast cancer survivors: a meta-review.Journal of cancer survivorship : research and practice · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Pooled it
  15. Enhancing Self-Esteem and Body Image of Breast Cancer Women through Interventions: A Systematic Review.International journal of environmental research and public health · 2021
    Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simone NardinDepartment of Translational Medicine, University of Eastern Piedmont, DIMET, Novara, Italy.
Edoardo MoraDepartment of Translational Medicine, University of Eastern Piedmont, DIMET, Novara, Italy.
Feba Mariam VarugheseDepartment of Translational Medicine, University of Eastern Piedmont, DIMET, Novara, Italy.
Francesca D'AvanzoDivision of Oncology, Ospedale Maggiore della Carità, Novara, Italy.
Ajay Ram VachanaramDepartment of Translational Medicine, University of Eastern Piedmont, DIMET, Novara, Italy.
Valentina RossiDivision of Oncology, Ospedale Maggiore della Carità, Novara, Italy.
Chiara SaggiaDivision of Oncology, Ospedale Maggiore della Carità, Novara, Italy.
Sara RubinelliDivision of Oncology, Ospedale Maggiore della Carità, Novara, Italy.
Alessandra GennariDepartment of Translational Medicine, University of Eastern Piedmont, DIMET, Novara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequent cancer in women: in 2018, almost two million cases have been diagnosed all over the world and it represents the principal cause of death from a neoplastic disease in women. In the past years, breast cancer prognosis has significantly improved over time: currently 5-year survival rates are in the range of 90%, and 10-year survival is about 80%. This improvement has been mostly observed in western countries, due to high coverage and compliance with screening programs, leading to early diagnosis, i.e., when the disease is at a subclinical level, and to an improvement in tumor molecular characterization and innovative systemic treatments. Yet the identification of different biological breast cancer subtypes prompted the development of innovative targeted agents and improved treatment personalization. On the other hand, longer survival rates and increasing proportions of cured patients require dedicated strategies to manage long-term sequelae of breast cancer treatments, with particular attention to quality of life. This review analyzes the most important issues, potentially occurring with cancer treatments, concerning long-term sequelae and quality of life, to define a global approach to breast cancer survivorship.

Indexed as

adjuvant therapy (AT)cardiotoxicityfertilitylifestyleosteoporosis

Identifiers

PMID32612947
PMCPMC7308500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.